|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
"""Social separation"" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation."
|
16724273 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors of patients with germ-line mutations in the BRCA1 and BRCA2 genes have more genetic defects than sporadic breast tumors.
|
11692153 |
2001 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors from BRCA1 mutation carriers are predominantly of basal subtype (i.e., triple negative), and BRCA2 mutation carriers are of luminal subtype (i.e., estrogen receptor positive).
|
17940826 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
|
19887619 |
2009 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors (n = 33) derived from BRCA2 999del5 mutation carriers were examined in terms of copy-number changes with high-resolution aCGH (array comparative genomic hybridization) containing 385 thousand probes (about one for each 7 kbp) and expression of phenotypic markers on TMAs (tissue microarrays).
|
21958427 |
2011 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors from BRCA2 mutation carriers showed significantly higher frequency of chromosome end-to-end fusions (CEFs) than tumors from non-carriers despite normal telomere DNA content.
|
22019625 |
2012 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
BRCA2 overexpression (but not underexpression) correlated significantly with Scarff, Bloom and Richardson (SBR) histopathological grade III (P=0.007) and was mainly attributed to nuclear polymorphism (P=0.005) and mitotic index (P=0.048), suggesting that the BRCA2 gene contributes to the proliferation rate in breast tumours.
|
10498873 |
1999 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
BRCA2 is a breast tumor suppressor with a potential function in the cellular response to DNA damage.
|
10551859 |
1999 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
BRCA2 has been found to be overexpressed in many breast tumors, suggesting that altered expression of the BRCA2 gene may contribute to breast tumorigenesis.
|
10961992 |
2000 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be either germline or somatically acquired.
|
27194814 |
2016 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
|
28825726 |
2017 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Adjuvant systemic therapy for breast cancer in BRCA1BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
|
20135344 |
2010 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.
|
18204050 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
An elevation of additional genetic defects in tumors of patients with germ-line mutation in the BRCA2 gene compared with sporadic breast tumors has been reported.
|
9766673 |
1998 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Association of breast tumor susceptibility gene products BRCA1 and BRCA2 with the RAD51 recombination protein suggested that cancer could arise through defects in recombination.
|
10362364 |
1999 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
At the BRCA2 locus, AI rates were 49% and 44% for ovarian and breast tumors, respectively.
|
11251173 |
2001 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Aurora-A amplification has been shown to be associated with breast tumors from BRCA2-mutation carriers and such patients might therefore be candidates for treatment with Aurora kinase inhibitors.
|
20960027 |
2012 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
|
12677558 |
2003 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
|
17257844 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
|
15365993 |
2004 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling.
|
12453858 |
2002 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
BRCA1 and BRCA2 in Indian breast cancer patients.
|
12442273 |
2002 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.
|
12442275 |
2002 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients.
|
15319244 |
2004 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
BRCA1 and BRCA2 mutations in Russian familial breast cancer.
|
11793480 |
2002 |